Luspatercept Clinical Trials
14 recruitingDrug
Phase 29Phase 32Phase 11
Showing 1–14 of 14 trials
Recruiting
Phase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled346 locationsNCT05564390
Recruiting
Phase 2
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Primary MyelofibrosisMyelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
GlaxoSmithKline68 enrolled33 locationsNCT06517875
Recruiting
Phase 3
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Myelodysplastic Syndromes
Bristol-Myers Squibb360 enrolled169 locationsNCT05949684
Recruiting
Phase 2
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
Anemia
Bristol-Myers Squibb189 enrolled36 locationsNCT05664737
Recruiting
Phase 2
Luspatercept + Darbepoetin in MDS
MDS (Myelodysplastic Syndrome)
Yale University60 enrolled3 locationsNCT07096297
Recruiting
Phase 2
Luspatercept for Clonal Cytopenias of Uncertain Significance
ThrombocytopeniaNeutropeniaAnemia+2 more
Weill Medical College of Cornell University50 enrolled1 locationNCT06788691
Recruiting
A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East
Bristol-Myers Squibb200 enrolled2 locationsNCT07215975
Recruiting
Phase 1Phase 2
Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT)
Acute Leukemia
Zhujiang Hospital46 enrolled1 locationNCT07362095
Recruiting
Phase 2
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
Myelodysplastic SyndromesMyeloproliferative NeoplasmAnemia
H. Lee Moffitt Cancer Center and Research Institute70 enrolled1 locationNCT05732961
Recruiting
Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Myelodysplastic Syndromes (MDS)
Celgene665 enrolled143 locationsNCT04064060
Recruiting
Phase 2
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes
M.D. Anderson Cancer Center40 enrolled1 locationNCT06113302
Recruiting
A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
Myelodysplastic Syndrome
Bristol-Myers Squibb104 enrolled2 locationsNCT06073860
Recruiting
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
Myelodysplastic SyndromesImmune ThrombocytopeniaAutoimmune Hemolytic Anemia+3 more
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico200 enrolled1 locationNCT05931718
Recruiting
Phase 2
The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
Lower Risk MDS Per IPSS-R
Institute of Hematology & Blood Diseases Hospital, China36 enrolled1 locationNCT05925504